Indivior Pharmaceuticals (INDV) Tax Provisions (2024 - 2026)

Indivior Pharmaceuticals' Tax Provisions history runs 3 years deep, the most recent figure standing at $26.0 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 136.36% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was $44.0 million, a 238.46% increase from a year earlier, with the FY2025 full-year figure at $29.0 million, up 123.08% from the prior year.
• Tax Provisions rose to $26.0 million in Q1 2026 per INDV's latest filing, from -$21.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $44.0 million in Q2 2025 and bottomed at -$23.0 million in Q2 2024.
• The 3-year median for Tax Provisions is $11.0 million (2024), against an average of $7.6 million.
• Biggest YoY gain for Tax Provisions was 291.3% in 2025; the steepest drop was 223.53% in 2025.
• Year by year, Tax Provisions stood at $17.0 million in 2024, then slumped by 223.53% to -$21.0 million in 2025, then surged by 223.81% to $26.0 million in 2026.
• Per Business Quant, the three latest INDV Tax Provisions figures stand at $26.0 million (Q1 2026), -$21.0 million (Q4 2025), and -$5.0 million (Q3 2025).